Analysts predict that Novavax, Inc. (NASDAQ:NVAX) will announce ($0.12) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for Novavax’s earnings, with estimates ranging from ($0.13) to ($0.11). Novavax posted earnings per share of ($0.14) in the same quarter last year, which would indicate a positive year-over-year growth rate of 14.3%. The firm is expected to announce its next earnings report on Wednesday, May 8th.

On average, analysts expect that Novavax will report full year earnings of ($0.41) per share for the current fiscal year, with EPS estimates ranging from ($0.51) to ($0.30). For the next financial year, analysts forecast that the business will report earnings of ($0.31) per share, with EPS estimates ranging from ($0.43) to ($0.18). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Novavax.

Novavax (NASDAQ:NVAX) last issued its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $6.13 million for the quarter, compared to analysts’ expectations of $7.87 million. During the same quarter last year, the company earned ($0.16) EPS.

NVAX has been the subject of a number of research analyst reports. Piper Jaffray Companies raised their price target on Novavax to $4.50 and gave the stock a “positive” rating in a research note on Thursday, January 3rd. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Novavax in a research report on Thursday, February 28th. BidaskClub raised Novavax from a “hold” rating to a “buy” rating in a research report on Monday, January 7th. Cantor Fitzgerald reissued a “hold” rating and set a $2.00 price objective on shares of Novavax in a research report on Tuesday, January 29th. Finally, JPMorgan Chase & Co. lowered Novavax from an “overweight” rating to an “underweight” rating in a research report on Thursday, February 28th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $2.94.

Several large investors have recently modified their holdings of NVAX. Baker BROS. Advisors LP bought a new position in shares of Novavax during the third quarter valued at $8,870,000. Pictet Asset Management Ltd. bought a new position in shares of Novavax during the third quarter valued at $5,619,000. Two Sigma Investments LP increased its holdings in Novavax by 223.6% in the 4th quarter. Two Sigma Investments LP now owns 3,282,564 shares of the biopharmaceutical company’s stock worth $6,040,000 after buying an additional 2,268,080 shares in the last quarter. Millennium Management LLC increased its holdings in Novavax by 127.8% in the 4th quarter. Millennium Management LLC now owns 2,934,275 shares of the biopharmaceutical company’s stock worth $5,399,000 after buying an additional 1,645,934 shares in the last quarter. Finally, Vanguard Group Inc increased its holdings in Novavax by 6.1% in the 3rd quarter. Vanguard Group Inc now owns 22,331,455 shares of the biopharmaceutical company’s stock worth $41,982,000 after buying an additional 1,291,644 shares in the last quarter. Hedge funds and other institutional investors own 41.41% of the company’s stock.

Shares of NVAX stock opened at $0.54 on Monday. Novavax has a 52 week low of $0.49 and a 52 week high of $2.58. The firm has a market capitalization of $238.77 million, a P/E ratio of -1.08 and a beta of 2.08.

About Novavax

Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.

See Also: How is a Moving Average Calculated?

Get a free copy of the Zacks research report on Novavax (NVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.